B
acterial vaginosis (BV) is a syndrome characterized by a change in vaginal ecology, where the normal flora of Lactobacillus morphotypes is replaced by a mixed microbial flora consisting of anaerobes and Gardnerella vaginalis, and an increase in the vaginal pH over 4.5; it often originates as a result of a reduction in, or in the absence of, Lactobacillus colonization and overgrowth of several facultative and obligate anaerobic bacteria [1, 2] . Bacterial vaginosis is considered as the most common form of vaginal infection among women of reproductive age affecting about 19% to 24% of them [3] . The prevalence of BV varies in different parts of the world; it is higher in developing countries. Moreover, 10% to 26% of pregnant women in the United States have been reported to suffer from BV. The disease has been found in 12% to 25% of women in routine clinic populations [4] . A clinical manifestation of BV is irritating malodorous vaginal discharge, especially a fishy odor, which is sometimes stronger after a woman had sex. Burning or discomfort during urination is a symptom of BV [5, 6] . Clinical studies have demonstrated an association between BV with adverse pregnancy outcomes [7] , such as premature rupture of membranes, preterm birth [8] , and postpartum endometritis. Women with upper genital tract infections such as pelvic inflammatory disease, endometritis, postgynecologic surgery infections, and cervicitis [9, 10] are more susceptible to having babies of low birth weight [11Y13] . It has also been suggested that the presence of BV increases the risk for human immunodeficiency virus infection [14Y16] . It is noteworthy that many women with BV do not show any symptoms [17] .
What patients with BV and their caregivers are mostly looking for is a treatment protocol to get them rid of the recurrence of the infection. Several methods have been offered for the treatment of BV. Either oral or vaginal metronidazole or vaginal clindamycin [18] provides equivalent treatment for BV in nonpregnant women. Oral clindamycin 300 mg twice daily for 7 days is an effective treatment. There is conflicting evidence regarding the efficacy of a single 2-g dose of oral metronidazole [19, 20] . As many as 30% of women relapse within 1 month of treatment and it is more common among women treated with topical compared with those treated with systemic antibiotics [21, 22] . Another alternative for the treatment of BV is the use of probioticsVlive microorganisms that, when consumed in appropriate amounts, confer a health benefit on the host [23] . When ingested, some of these probiotic microorganisms are able to resist the physicochemical conditions prevailing in the digestive tract [16, 24Y26] . The term ''probiotic'' is an etymological hybrid derived from Greek and Latin meaning ''for life'' [25] . Traditionally, yogurt was the first food to which probiotics were added. Recently, development of novel probiotic foods has attracted great attention, and manufacturers are coming out with new products including ice cream, cheese, chocolate, beverages, cereals, and vegetable products. Different forms of probiotic supplements are also available in the market today, including pills, capsules, tablets, gel caps, liquids, and powders [27] . Both foods and supplements have been used as carriers for probiotics in clinical trials investigating the health benefits of probiotics. Some mostly documented health effects of probiotics are relief of diarrhea, improvement in lactose intolerance, relief of respiratory and urinary tract infections, and immunomodulatory, anticarcinogenic, antidiabetic, hypocholesterolemic, and hypotensive properties [28Y30] . By reducing inflammatory responses, probiotics have been shown to correct insulin sensitivity and reduce development of diabetes mellitus [28, 31] . A beneficial effect of ''lactic acidYproducing'' microorganisms on vaginal microbiota has also been suggested about 100 years ago [23, 32] .
MATERIALS AND METHODS
To review the available evidence on the efficacy of probiotics in the prevention and treatment of BV, randomized controlled trials were searched in PubMed, Science Direct, and Cochrane Database between 1990 and 2011. The search terms included probiotics, Lactobacillus, bacterial vaginosis, and urinary tract infections.
Application of Probiotics in BV Treatment
There are important issues to which great attention must be paid regarding the effects of probiotics on BV treatment and prevention. The basis for use of probiotics in BV treatment was developed in 1973, when healthy women with no history of urinary tract infection were reported to have lactobacilli in their vagina [17] . Lactobacillus organisms that predominate in the vagina of healthy women spread from their rectum and perineum and form a barrier to the entry of uropathogens from the vagina into the bladder [33] . Similar to pathogenic bacteria with colonic origin, which cause urogenital disorders, probiotic bacteria must be capable of ascending to the vaginal tract after passing out from the rectum. This application is also justified by observations that the normal vaginal microbiota colonizes from an intestinal origin, which means that microbial ascension is a natural process actually contributing to the development of a healthy vaginal microbiota in the host [34] ; this has been shown by a number of clinical trials as well [35] . Probiotics are believed to protect the host against infections by means of several mechanisms including the following: (1) occupation of specific adhesion sites at the epithelial surface of the urinary tract; (2) maintenance of a low pH and production of antimicrobial substances like acids, hydrogen peroxide, and bacteriocins; (3) degradation of polyamines; and (4) the production of surfactants with antiadhesive properties [36, 37] . Probiotics have been administered both orally and vaginally; however, it is still not clear as to which route is more efficient. Foods and supplements have been used as carriers when oral administration was aimed; no studies have compared the efficacy of these 2 methods. Not all strains have exerted the desired effects in the patients; poor colonization of some strains in the vagina could be a reason [34, 38, 39] . The most profitable dose and treatment duration must be taken into consideration as well. Figure 1 summarizes the process through which a healthy woman is infected with BV and how probiotics may provide protection against this disease ( Figure 1 ).
Clinical Trials of Probiotics in the Treatment or Prevention of BV
Probiotics have been administered through 2 routes in attempt to prevent BV: vaginal and oral. In studies that use vaginal form, probiotics must colonize the vagina to confer the benefits claimed for them. Therefore, they have to reach the organ intact. Vaginal probiotic capsules and cream have widely been used, by means of which, the probiotic bacteria are directly introduced into the vagina [40] . Oral method, on the other hand, has been introduced in an attempt to come up with a more practical route that could also prevent BV in healthy women as well as present the consumer with other health benefits of these beneficial microorganisms [39, 41] . A study by Marcone et al. [42] indicated that oral capsules containing a variety of probiotic bacteria including Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 at a dose of 2.5 Â 10 9 CFU for 14 days after metronidazole therapy reduced the Nugent score in 3 subjects of the intervention group, while no improvement was observed in subjects of the control group. A similar study by Anukam et al. [36] showed that, after oral administration of capsules containing either 1.0 Â 10 9 CFU of L. rhamnosus GR-1 and L. reuteri RC-for 7 days, BV cure rate was 88% in probiotic group versus 40% in the placebo group. In the same way, Neri et al. [43] confirmed that an amount of 10 9 CFU of L. [52, 61, 62] . According to a general theory, a probiotic must have 2 criteria to be selected as an efficient strain in the treatment of urogenital infections: 1) it must be able to colonize the host without any adverse side effects and 2) it must be capable of inhibiting urogenital pathogens [65] . According to Reid and Bruce [39] , different probiotic bacteria have varying capabilities to colonize the vagina of different patients; this indicates the importance of using a combination of strains in probiotic products [33, 64] . Oral administration of L. acidophilus, or intravaginal administration of L. acidophilus or L. rhamnosus GR-1 and L. fermentum RC-14, has been documented to most efficiently increase the numbers of vaginal lactobacilli, restore the vaginal microbiota to normal, and to cure women with BV [52] .
Researchers have tried different dosages in their attempts to treat BV with probiotics, many of which have resulted in positive outcomes. There is strong evidence that BV is most appropriately treated when more than 10 8 viable organisms per day are used [25, 65] . However, the minimum dose that can generally confer the favored benefits in women must be determined.
A major concern regarding BV is that the patients usually complain of the recurrences of the disease. Thus, Oral capsules containing 2.5 Â 10 9 CFU of L. rhamnosus GR-1 and L. reuteri RC-14, 14 d
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The median difference in Nugent scores between baseline and the end of the study was 3 in the intervention group and 0 in the control group Petricevic et al. [57] Vaginal tablets containing 10 6 CFU of 
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Probiotic prophylaxis resulted in lower recurrence rates for BV women Ya et al. [45] seeking for treatments that prevent the recurrence of BV as well may be a priority. Probiotics are a good option to fulfill this goal, provided that they are properly colonized in the vagina. Parent et al. [4] found that cure was more common, and the number of vaginal lactobacilli was significantly higher, in women with BV at both 2 and 4 weeks after the start of a 6-day treatment with L. acidophilus and estriol, when compared to women with BV who received a placebo. However, most clinical trials have reported that 2 months of oral administration of L. acidophilus, L. rhamnosus GR-1, and L. fermentum RC-14 can be more effective in preventing recurrences of BV and/or increasing vaginal colonization with lactobacilli, thus restoring the normal vaginal microbiota [66] ( Table 1) .
CONCLUSIONS
Lactobacilli strains are probiotic bacteria. Probiotics are live microorganisms that confer a health benefit on the host when administered in adequate amounts [69] . Results of studies of lactobacilli for the treatment of BV in women were inconclusive but promising. Various in vitro studies have shown that specific strains of lactobacilli inhibit the growth of bacteria causing BV by producing H 2 O 2 , lactic acid, and/or bacteriocins and/or inhibit the adherence of G. vaginalis to the vaginal epithelium. Most relevant clinical trials have suggested that oral administration of L. acidophilus, or intravaginal administration of L. acidophilus or L. rhamnosus GR-1 and L. fermentum RC-14, is able to increase the numbers of vaginal lactobacilli, to restore the vaginal microbiota to normal, and to cure women of BV, although several trials demonstrated intravaginal instillation of lactobacilli had no significant effect on the treatment of BV. The dominance of lactobacilli in healthy vaginal microbiota and its obliteration in BV have given rise to the concept of oral or vaginal instillation of probiotic Lactobacillus strains to restore the balance. Indeed, available evidence now indicates that certain strains of lactobacilli administered intravaginally are capable of colonizing the vagina.
This review confirms the influence of lactobacilli as an adjuvant to standard treatment with antibiotics, nonchemotherapeutic means to restore and maintain a normal urogenital flora, and shows that probiotic bacteria especially L. acidophilus, L. rhamnosus GR-1, and L. fermentum RC-14 when administered over 10 8 CFU for 2 months can most appropriately normalize the vaginal flora, help cure the existing infection, and prevent recurrence of BV. Longer periods of probiotic administration may be useful for long-term control of BV relapses after conventional therapy with metronidazole. Probiotics have been reported useful when used either vaginally or orally; foods and supplements have both been shown to be efficient vehicles as well. However, because BV is a common disorder for the prevention of which the vaginal flora needs to be normal and devoid of pathogens by the help of beneficial bacteria, suggesting women to consume probiotic foods will not only protect them against BV but will also reward them with other health benefits of probiotics.
